Related Experiment Videos
[A study on ceftriaxone in the perinatal period]
Z Takase1, M Fujiwara, T Miyoshi
1Department of Obstetrics and Gynecology, Kawasaki Medical School.
The Japanese Journal of Antibiotics
|February 1, 1988
Summary
Ceftriaxone (CTRX) effectively treats perinatal infections, showing good transfer into umbilical cord serum and amniotic fluid with no observed side effects in mothers or neonates.
Area of Science:
- Pharmacokinetics and Pharmacology
- Maternal-Fetal Medicine
- Infectious Diseases
Context:
- Ceftriaxone (CTRX) is a novel cephem antibiotic with broad-spectrum activity.
- Perinatal infections pose significant risks to mothers and newborns.
- Understanding antibiotic pharmacokinetics during pregnancy is crucial for safe and effective treatment.
Purpose:
- To evaluate the pharmacokinetic profile of Ceftriaxone (CTRX) in mothers during the perinatal period.
- To assess the transfer of CTRX into fetal circulation and amniotic fluid.
- To determine the safety and efficacy of CTRX for treating perinatal infections.
Summary:
- Intravenous administration of 1g CTRX to 30 mothers resulted in a peak maternal serum concentration of 135 µg/ml within 20-25 minutes.
- CTRX demonstrated significant transfer into umbilical cord serum (approx. 20% of maternal levels) and amniotic fluid (approx. 10% of maternal levels).
- No adverse effects were reported in mothers or neonates during the study period.
Impact:
- Ceftriaxone (CTRX) exhibits favorable pharmacokinetic properties and a good safety profile for use in the perinatal period.
- The drug's ability to cross into fetal compartments suggests potential therapeutic benefit for intrauterine infections.
- CTRX is identified as a valuable antibiotic option for managing Gram-positive and Gram-negative bacterial infections in pregnant women and newborns.